AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18405128 — intervention group
Group type: EXPERIMENTAL
Intervention: EGI
Number of subjects: 1659
Study 15033497 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ER)
Number of subjects: 43
Study 15033497 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit Reversal (HR)
Number of subjects: 43
Study 11878407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg/saquinavir 400 mg twice daily plus one NRTI
Number of subjects: 90
Study 11878407 — intervention group
Group type: COMPARATOR
Intervention: Indinavir 800 mg once every 8 hours plus two NRTIs
Number of subjects: 90
Study 9894650 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous lead system with additional subcutaneous lead
Number of subjects: 20
Study 9894650 — intervention group
Group type: COMPARATOR
Intervention: Transvenous lead system only
Number of subjects: 20
Study 8000154 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased trace element intake (4.5 mg Cu, 190 micrograms Se, and 40 mg Zn/day)
Number of subjects: 10
Study 8000154 — intervention group
Group type: COMPARATOR
Intervention: Standard trace element intake (control group)
Number of subjects: 10
Study 3276620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 34
Study 3276620 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 34
Study 31608373 — intervention group
Group type: EXPERIMENTAL
Intervention: Program 4 (community-based HIV care program + nutritional education + food supplement)
Number of subjects: 600
Study 31608373 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs 3 (community-based HIV care program + food supplement) and 4 (all elements of Programs 1-3)
Number of subjects: 600
Study 31608373 — intervention group
Group type: COMPARATOR
Intervention: Program 1 (community-based HIV care program)
Number of subjects: 600
Study 29055711 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido (DN) cardioplegia
Number of subjects: 100
Study 29055711 — intervention group
Group type: COMPARATOR
Intervention: St Thomas (STH) cardioplegia
Number of subjects: 100
Study 26009908 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF+ (Platelet-rich fibrin applied)
Number of subjects: 20
Study 26009908 — intervention group
Group type: COMPARATOR
Intervention: PRF- (No platelet-rich fibrin applied)
Number of subjects: 20
Study 23829407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education and psychosocial support programme
Number of subjects: 155
Study 23829407 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 155
Study 21564071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg weekly for 8 weeks, then 15 mg weekly for ER, 20 mg weekly for 4 weeks for LR, or 25 mg weekly for LN if not achieving PASI 50.
Number of subjects: 103
Study 21564071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 20 mg weekly for late responders (LR) after initial 15 mg weekly.
Number of subjects: 103
Study 21564071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg weekly for late nonresponders (LN) if not achieving PASI 50 at week 12.
Number of subjects: 103
Study 19097663 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Number of subjects: 200
Study 19097663 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based parameters during MTT
Number of subjects: 200
Study 19097663 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 200
Study 16854694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation
Number of subjects: 60
Study 16854694 — intervention group
Group type: EXPERIMENTAL
Intervention: Halogen light stimulation
Number of subjects: 60
Study 16854694 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 60
Study 14514222 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 mm neck implants
Number of subjects: 12
Study 14514222 — intervention group
Group type: COMPARATOR
Intervention: Neck implants
Number of subjects: 12
Study 11097959 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 12 weeks
Number of subjects: 65
Study 11097959 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 elderly comparison subjects)
Number of subjects: 65
Study 9357931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age groups (25-28 weeks and 28-30 weeks)
Number of subjects: 100
Study 9357931 — intervention group
Group type: COMPARATOR
Intervention: Sick infants
Number of subjects: 100
Study 9357931 — intervention group
Group type: COMPARATOR
Intervention: Healthy infants
Number of subjects: 100
Study 9357931 — intervention group
Group type: EXPERIMENTAL
Intervention: rT3 levels
Number of subjects: 100
Study 8403788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone infusion study (glucagon, adrenaline, noradrenaline, cortisol, growth hormone)
Number of subjects: 10
Study 8403788 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycaemia study (plasma glucose lowered to 2.8 mmol/l)
Number of subjects: 10
Study 6325525 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association Hyperlipidemia Diet C (AHA, N = 23)
Number of subjects: 50
Study 6325525 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fiber, low fat diet based on the Pritikin maintenance diet (HFD, N = 27)
Number of subjects: 50
Study 30877742 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mZnO (20.90 m2/g)
Number of subjects: 480
Study 30877742 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized ZnO groups (S-mZnO, M-mZnO, L-mZnO)
Number of subjects: 480
Study 30877742 — intervention group
Group type: COMPARATOR
Intervention: Control group (ZnSO4)
Number of subjects: 480
Study 29176386 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentages of maximal voluntary isometric contraction (MVIC)
Number of subjects: 20
Study 29176386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of perceived exertion (RPE)
Number of subjects: 20
Study 26414653 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg)
Number of subjects: 100
Study 26414653 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg)
Number of subjects: 100
Study 26414653 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg) and Diclofenac (75 mg)
Number of subjects: 100
Study 24671918 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access (TR)
Number of subjects: 103
Study 24671918 — intervention group
Group type: COMPARATOR
Intervention: Femoral access (TF)
Number of subjects: 103
Study 24671918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TR and TF
Number of subjects: 103
Study 20553134 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 60
Study 20553134 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% prilocaine with 1:200,000 epinephrine
Number of subjects: 60
Study 20553134 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% prilocaine
Number of subjects: 60
Study 15585547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 173
Study 15585547 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study 11597011 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive Seed Localization (RSL)
Number of subjects: 97
Study 11597011 — intervention group
Group type: COMPARATOR
Intervention: Wire Localization (WL)
Number of subjects: 97
Study 9521394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone
Number of subjects: 0
Study 9521394 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 0
Study 7805083 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis against venous thrombosis (mechanical and pharmacologic modalities)
Number of subjects: 200000
Study 7805083 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for DVT based on anatomic extent of thrombus
Number of subjects: 200000
Study 2642875 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate + ethanol
Number of subjects: 12
Study 2642875 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate + ethanol placebo
Number of subjects: 12
Study 2642875 — intervention group
Group type: COMPARATOR
Intervention: sucralfate placebo + ethanol
Number of subjects: 12
Study 2642875 — intervention group
Group type: COMPARATOR
Intervention: sucralfate placebo + ethanol placebo
Number of subjects: 12
Study 2642875 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 12
Study 2642875 — intervention group
Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 12
Study 1086428 — intervention group
Group type: EXPERIMENTAL
Intervention: Total shunt
Number of subjects: 48
Study 1086428 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective shunt (performed)
Number of subjects: 48
Study 1086428 — intervention group
Group type: COMPARATOR
Intervention: Selective shunt (randomized)
Number of subjects: 48
Study 31726034 — intervention group
Group type: EXPERIMENTAL
Intervention: EGP‐437 delivered by iontophoresis (days 0 and 7)
Number of subjects: 193
Study 31726034 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% (PA 1%) self-administered daily (tapered schedule, days 0‐28)
Number of subjects: 193
Study 31726034 — intervention group
Group type: EXPERIMENTAL
Intervention: EGP‐437
Number of subjects: 193
Study 31726034 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% (PA 1%)
Number of subjects: 193
Study 28481825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up education program (NP-FEP), contacted by telephone 11 times over a 6-month period.
Number of subjects: 403
Study 28481825 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up education (control group).
Number of subjects: 403
Study 27855719 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness-focused interactive booklet
Number of subjects: 20000
Study 27855719 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 20000
Study 24643710 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet therapy
Number of subjects: 186
Study 22859320 — intervention group
Group type: EXPERIMENTAL
Intervention: Original salbutamol (5 mg, 20 drops in nebulizing solution)
Number of subjects: 126
Study 22859320 — intervention group
Group type: COMPARATOR
Intervention: Similar salbutamol (5 mg, 20 drops in nebulizing solution)
Number of subjects: 126
Study 22859320 — intervention group
Group type: EXPERIMENTAL
Intervention: Original salbutamol
Number of subjects: 126
Study 22859320 — intervention group
Group type: COMPARATOR
Intervention: Similar salbutamol
Number of subjects: 126
Study 22859320 — intervention group
Group type: EXPERIMENTAL
Intervention: Original salbutamol vs Similar salbutamol
Number of subjects: 126
Study 21211337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone injection (62.5 mg/ml) infused at a rate of 10 microl/h for 14 days
Number of subjects: 113
Study 21211337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 113
Study 18498922 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 590
Study 18498922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study 15711315 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (Proscar)
Number of subjects: 2981
Study 15711315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2981
Study 12742294 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 12
Study 12742294 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 12
Study 12742294 — intervention group
Group type: COMPARATOR
Intervention: Bucindolol (a beta-blocker)
Number of subjects: 12
Study 14564594 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 8 ml of physiological saline after spinal hyperbaric tetracaine
Number of subjects: 40
Study 14564594 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 8 ml of physiological saline after spinal isobaric tetracaine
Number of subjects: 40
Study 14564594 — intervention group
Group type: COMPARATOR
Intervention: Spinal hyperbaric tetracaine without epidural injection
Number of subjects: 40
Study 14564594 — intervention group
Group type: COMPARATOR
Intervention: Spinal isobaric tetracaine without epidural injection
Number of subjects: 40
Study 8638527 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 8638527 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of the renin-angiotensin system
Number of subjects: 0
Study 1832634 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind biopsy using a 2.0-mm Tru-cut needle
Number of subjects: 120
Study 1832634 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-guided biopsy using a 2.0-mm Tru-cut needle
Number of subjects: 120
Study 1832634 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of postbiopsy hematoma formation
Number of subjects: 120
Study 1832634 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Blind and Laparoscopy-guided)
Number of subjects: 120
Study 6349142 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid sutures
Number of subjects: 302
Study 6349142 — intervention group
Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 302
Study 31005178 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D transthoracic echocardiography (2D TTE)
Number of subjects: 259
Study 30125448 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 1 (n=23): Key features of work well-being identified as workload (n=14), job satisfaction (n=13), and support (n=13).
Number of subjects: 65
Study 30125448 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 2 (n=25): Highest rated elements included feeling valued, respect, support, work-life balance, and workplace culture.
Number of subjects: 65
Study 30125448 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 3 (n=17): Mean score for central narrative was 7.88 and for peripheral narrative was 7.38.
Number of subjects: 65
Study 27448700 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity atorvastatin (40 mg/day)
Number of subjects: 591
Study 27448700 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity atorvastatin (20 mg/day)
Number of subjects: 591
Study 24593323 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U of NTC
Number of subjects: 272
Study 24593323 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxin A
Number of subjects: 272
Study 24593323 — intervention group
Group type: EXPERIMENTAL
Intervention: NTC
Number of subjects: 272
Study 21915941 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial Fourier-ICA applied to resting-state and naturalistic stimulation MEG data
Number of subjects: 9
Study 21915941 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial Fourier-ICA
Number of subjects: 9
Study 20164274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon with a four‐winged apertured film cover
Number of subjects: 69
Study 20164274 — intervention group
Group type: COMPARATOR
Intervention: Commercial tampon with a nonwoven cover
Number of subjects: 69
Study 17283260 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 893
Study 17283260 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d
Number of subjects: 893
Study 15629605 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with hyperthermia (minimum of five sessions, 60 min each, once per week)
Number of subjects: 110
Study 15629605 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 110
Study 11869407 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula
Number of subjects: 110
Study 11869407 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 110
Study 10198862 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric corneal tunnel incisions with an L‐shaped entrance and a concave exit
Number of subjects: 0
Study 10198862 — intervention group
Group type: COMPARATOR
Intervention: Conventional symmetric linear incisions
Number of subjects: 0
Study 7780258 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic needle insertion
Number of subjects: 18
Study 7780258 — intervention group
Group type: COMPARATOR
Intervention: Manual pen
Number of subjects: 18
Study 2184874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory integration (SI) sessions, about 13 weekly sessions, each of 1 hour duration
Number of subjects: 74
Study 2184874 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 74
Study 385456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisate treatment
Number of subjects: 40
Study 385456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 30955043 — intervention group
Group type: EXPERIMENTAL
Intervention: Active working memory training
Number of subjects: 123
Study 30955043 — intervention group
Group type: COMPARATOR
Intervention: Control working memory training
Number of subjects: 123
Study 27569433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training video
Number of subjects: 150
Study 27569433 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy
Number of subjects: 150
Study 24687433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented highly porous metal tibia
Number of subjects: 397
Study 24687433 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented highly porous metal tibia
Number of subjects: 397
Study 24687433 — intervention group
Group type: COMPARATOR
Intervention: Traditional modular cemented tibia
Number of subjects: 397
Study 23827078 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (LA)
Number of subjects: 120
Study 23827078 — intervention group
Group type: COMPARATOR
Intervention: methycobal
Number of subjects: 120
Study 21917766 — intervention group
Group type: COMPARATOR
Intervention: ELND005 250 mg
Number of subjects: 353
Study 21917766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 19074463 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T(4) withdrawal (37 days); 21 patients received (131)I (2.02+/‐0.22 GBq; 54.6+/‐5.9 mCi)
Number of subjects: 42
Study 19074463 — intervention group
Group type: COMPARATOR
Intervention: rhTSH stimulation; 21 patients received (131)I (1.97+/‐0.18 GBq; 53.2+/‐4.9 mCi) 24 h after rhTSH (0.9 mg)
Number of subjects: 42
Study 16696817 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg o.d.
Number of subjects: 17
Study 16696817 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg b.d.
Number of subjects: 17
Study 16696817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15291218 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of information regarding the relationship between choice and outcome
Number of subjects: 40
Study 15291218 — intervention group
Group type: COMPARATOR
Intervention: Direct contact with the underlying contingencies
Number of subjects: 40
Study 11737382 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg per day)
Number of subjects: 374
Study 11737382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 11737382 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 374
Study 11737382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Itraconazole and Placebo)
Number of subjects: 374
Study 9764979 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment for 24 weeks
Number of subjects: 30
Study 7889617 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg rhIGF‐I
Number of subjects: 12
Study 7889617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3148471 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0
Study 3148471 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 0
Study 3148471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3148471 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol
Number of subjects: 0
Study 30388273 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing Tobacco Through Organizational Change (ATTOC)
Number of subjects: 456
Study 30388273 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 456
Study 30058418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VitC) treatment group
Number of subjects: 280
Study 30058418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VitC) non-treatment group
Number of subjects: 280
Study 30058418 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without EMs)
Number of subjects: 280
Study 27401361 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Burden of COPD (ABC) tool
Number of subjects: 357
Study 27401361 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 357
Study 24667180 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence and creative activity intervention delivered by retired senior volunteers (RSVs) through three home visits.
Number of subjects: 45
Study 24667180 — intervention group
Group type: COMPARATOR
Intervention: Supportive telephone calls by research staff (Control group).
Number of subjects: 45
Study 24667180 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence and creative activity intervention delivered by RSVs.
Number of subjects: 45
Study 22850141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study 20951287 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac irrigation
Number of subjects: 7
Study 20951287 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle irrigation
Number of subjects: 7
Study 17484941 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline interviews completed within 1 month of victimization
Number of subjects: 541
Study 17484941 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of posttraumatic distress
Number of subjects: 541
Study 17484941 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of distress levels
Number of subjects: 541